Charles Schwab Investment Management Inc. lessened its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by ...

Neuren Pharmaceuticals (ASX:NEU) is focused on neurodevelopmental disorders and rare disease drug development.In this ...

Existing research indicates that the accuracy of a Parkinson’s disease diagnosis hovers between 55% and 78% in the first five years of assessment. That’s partly because Parkinson’s sibling movement ...

Reports Q4 revenue $22.6M, consensus $4.28M. Revenue recognized for upfront license fees and services provided from the License and ...

Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) have earned a consensus rating of “Moderate Buy” from ...

We recently published a list of 12 Best Nasdaq Stocks Under $20 to Buy Now. In this article, we are going to take a look at ...

Learn more about whether ACADIA Pharmaceuticals Inc. or Merus N.V. is a better investment based on AAII's A+ Investor grades, ...

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on March 5, 2025, the Compensation Committee of Acadia’s Board of Directors (the "Committee") granted inducement awards consisting of ...

The Nasdaq has had a challenging start to 2025, with the index dropping nearly 12% YTD, as of March 13. March 10 marked its worst single-day decline in almost two years, plunging 4% as investor ...

Detailed price information for Proqr Therapeutics (PRQR-Q) from The Globe and Mail including charting and trades.

Saniona (OMX: SANION), a clinical stage biopharmaceutical company, today announced that the ongoing ion channel research collaboration with Boehringer Ingelheim has been extended with one year. "The p ...

A former pharmaceutical executive traded on nonpublic information about an antipsychotic drug’s development, avoiding $1.3 ...